.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

EP. 1: The Intravenous Administration of Monoclonal Antibodies

May 13th 2020

EP. 2: Intravenous Administration and Hepatitis

May 13th 2020

EP. 3: Medication Supplements Prior to IV Administration

May 13th 2020

EP. 4: Infusion-Related Adverse Events

May 13th 2020

EP. 5: Study Overview: COLUMBA and PLEIADES

May 13th 2020

EP. 6: Real-World Experience With SQ Monoclonal Antibodies

May 13th 2020

EP. 7: Community Advice: SQ Formulation of Daratumumab

May 13th 2020